Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05621746 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct

StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Novo Nordisk A/S to Novo Nordisk A/S Show 6 more changesShow less
    • Trial completed
    • Final enrollment: 123 participants (planned 100)
    • Primary completion date changed from estimate of Jun 30, 2026 to Apr 30, 2026
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 5 of 6 entries
    • Site details revised
  2. Primary and study completion dates: Feb 14, 2025 to Jun 30, 2026v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 4, 2023 to Nov 23, 2022
    v3
  5. Start date: Nov 11, 2022 to Jan 4, 2023v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novo Nordisk
268 trials monitored
See 15 trials at risk
Hemophilia
241 trials monitored
See 12 trials at risk
This study will collect information on the long term health of joints in people with haemophilia A who have started treatment with Esperoct within twelve months prior to participation to the study. This study is conducted to look at how joint health of people with haemophilia changes over time when they are receiving the medicine Esperoct. The participants will get Esperoct as prescribed to the participants by the study doctor. The participant's treatment will not be affected by their involvement in the study. Every six months, the participants will be asked to answer some questionnaires about their joints, their pain and their ability to be physically active. Their participation in the study will last for no more than 2 years. The participants are free to leave the study at any time and for any reason. This will not affect their current and future medical care.
Trial Details
NCT Number NCT05621746
Lead Sponsor Novo Nordisk A/S
Conditions
(from sponsor)		 Haemophilia A
Related terms Hemophilia A
Enrollment 123 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov